OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. More Details
Flawless balance sheet with high growth potential.
Share Price & News
How has OraSure Technologies's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: OSUR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: OSUR's weekly volatility (8%) has been stable over the past year.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: OSUR exceeded the US Medical Equipment industry which returned 31.9% over the past year.
Return vs Market: OSUR exceeded the US Market which returned 36.2% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is OraSure Technologies's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StOraSure Technologies, Inc. (NASDAQ:OSUR) Shares Could Be 30% Below Their Intrinsic Value Estimate
3 months ago | Simply Wall StResults: OraSure Technologies, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
4 months ago | Simply Wall StCan You Imagine How Jubilant OraSure Technologies' (NASDAQ:OSUR) Shareholders Feel About Its 115% Share Price Gain?
Is OraSure Technologies undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: OSUR ($10.3) is trading above our estimate of fair value ($4.67)
Significantly Below Fair Value: OSUR is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: OSUR is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: OSUR is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate OSUR's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: OSUR is good value based on its PB Ratio (1.9x) compared to the US Medical Equipment industry average (5x).
How is OraSure Technologies forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OSUR is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: OSUR is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: OSUR's is expected to become profitable in the next 3 years.
Revenue vs Market: OSUR's revenue (23.3% per year) is forecast to grow faster than the US market (10% per year).
High Growth Revenue: OSUR's revenue (23.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: OSUR's Return on Equity is forecast to be low in 3 years time (3.9%).
How has OraSure Technologies performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OSUR is currently unprofitable.
Growing Profit Margin: OSUR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: OSUR is unprofitable, and losses have increased over the past 5 years at a rate of 21.3% per year.
Accelerating Growth: Unable to compare OSUR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OSUR is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (10.1%).
Return on Equity
High ROE: OSUR has a negative Return on Equity (-3.74%), as it is currently unprofitable.
How is OraSure Technologies's financial position?
Financial Position Analysis
Short Term Liabilities: OSUR's short term assets ($288.9M) exceed its short term liabilities ($46.5M).
Long Term Liabilities: OSUR's short term assets ($288.9M) exceed its long term liabilities ($9.4M).
Debt to Equity History and Analysis
Debt Level: OSUR is debt free.
Reducing Debt: OSUR has not had any debt for past 5 years.
Debt Coverage: OSUR has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: OSUR has no debt, therefore coverage of interest payments is not a concern.
What is OraSure Technologies's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate OSUR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate OSUR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OSUR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OSUR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of OSUR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Steve Tang (59 yo)
Dr. Stephen S. Tang, also known as Steve, Ph.D. has been President and Chief Executive Officer at OraSure Technologies, Incorporation since April 01, 2018. Dr. Tang has been Chief Executive Officer and Pre...
CEO Compensation Analysis
Compensation vs Market: Steve's total compensation ($USD2.11M) is about average for companies of similar size in the US market ($USD2.21M).
Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.
|CFO & Principal Accounting Officer||2.75yrs||US$1.20m||0.15% |
|Senior VP||1.08yrs||US$958.27k||0.20% |
|Executive VP & Business Unit Leader of Molecular Solutions||8.33yrs||US$868.56k||0.16% |
|Vice President of Corporate Communications||2.58yrs||no data||no data|
|Executive VP & Business Unit Leader of Infectious Disease||0.83yr||no data||0.047% |
|VP of Finance||2.42yrs||no data||0.023% |
Experienced Management: OSUR's management team is considered experienced (2.6 years average tenure).
|Independent Director||0.92yr||no data||0.022% |
|Independent Director||5yrs||US$183.31k||0.048% |
|Independent Director||17.83yrs||US$185.00k||0.033% |
|Independent Chairman of the Board||2.92yrs||US$220.00k||0.093% |
|Independent Director||1.58yrs||US$124.98k||0.025% |
|Independent Director||3.75yrs||US$170.00k||0.037% |
|Director||0.75yr||no data||0.0097% |
Experienced Board: OSUR's board of directors are considered experienced (3.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16%.
OraSure Technologies, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: OraSure Technologies, Inc.
- Ticker: OSUR
- Exchange: NasdaqGS
- Founded: 2000
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: US$741.039m
- Shares outstanding: 71.95m
- Website: https://www.orasure.com
Number of Employees
- OraSure Technologies, Inc.
- 220 East First Street
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|OSUR||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Nov 1986|
|EP3||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Nov 1986|
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and inter...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/03/08 00:31|
|End of Day Share Price||2021/03/05 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.